Key regions: United Kingdom, Germany, France, South Korea, Italy
Pakistan, like many other countries, has been grappling with the COVID-19 pandemic since early 2020. As the world races to vaccinate its populations against the virus, the COVID-19 Vaccines market in Pakistan has been developing in a certain way.
Customer preferences: In Pakistan, there is a strong preference for locally produced goods, and this trend extends to the pharmaceutical industry. As such, there has been a growing demand for locally produced COVID-19 vaccines. However, the lack of local manufacturing capabilities has meant that Pakistan has had to rely on imports to meet its vaccination needs.
Trends in the market: The COVID-19 Vaccines market in Pakistan has been dominated by the Chinese-made Sinopharm vaccine, which has been approved for emergency use in the country. Other vaccines, such as the AstraZeneca vaccine, have also been approved for use in Pakistan, but their availability has been limited. The government has been working to secure more vaccine doses from various sources to meet the growing demand.
Local special circumstances: Pakistan has a large population, and its healthcare system is already under strain due to a lack of resources. The COVID-19 pandemic has only exacerbated this issue, and the government has been struggling to provide adequate healthcare services to its citizens. The vaccination drive has also faced challenges, such as vaccine hesitancy among some segments of the population.
Underlying macroeconomic factors: Pakistan's economy has been struggling in recent years, and the COVID-19 pandemic has only made things worse. The country has been facing a severe economic crisis, with high inflation and unemployment rates. The government has been trying to address these issues through various measures, such as stimulus packages and economic reforms. However, the pandemic has made it difficult to achieve meaningful progress in these areas.In conclusion, the COVID-19 Vaccines market in Pakistan has been developing in a certain way due to factors such as customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. While the government has been working to secure more vaccine doses and address the challenges facing the healthcare system, it remains to be seen how successful these efforts will be in the long run.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
